Viewing Study NCT06357533

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:43 AM
Ignite Modification Date: 2026-01-07 @ 8:58 AM
Study NCT ID: NCT06357533
Status: RECRUITING
Last Update Posted: 2025-10-27
First Post: 2024-04-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None Non-Small Cell Lung Cancer View
None Datopotamab Deruxtecan View
None Rilvegostomig View
None Pembrolizumab View
None Non-squamous View
None PD-L1 expression >=50% View
None Locally-advanced NSCLC View
None Metastatic NSCLC View